Streetbeat News

Products Services

HRMY

Harmony Biosciences (NASDAQ:HRMY) has been evaluated by 6 analysts over the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $38.5, down 30.63% from the previous $55.50. Recent analyst actions include maintaining, raising, and lowering ratings and price targets. Harmony Biosciences is a commercial-stage pharmaceutical company with a focus on rare neurological diseases. Financially, the company has shown strong performance with a revenue growth rate of 36.74%, a net margin of 24.0%, an ROE of 7.96%, an ROA of 5.0%, and a low debt-to-equity ratio of 0.41.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 2:01 pm

NVS

VYGR

Voyager Therapeutics' stock is up following the announcement of a strategic collaboration and capsid license agreement with Novartis for gene therapies targeting Huntington's disease and spinal muscular atrophy.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:58 pm

VFS

VinFast Auto Ltd (NASDAQ:VFS), a Vietnamese EV maker, has signed agreements with five dealerships in the U.S. to sell its electric vehicles, starting with the VF 8 SUV. The company plans to expand its U.S. dealer network to 125 locations and currently operates 13 stores in California. Despite this expansion, VFS shares dropped by 4.78% to $7.97 in premarket trading.

Portfolio Pulse from Shivani Kumaresan

January 02, 2024 | 1:52 pm

CLSK

MARA

RIOT

Bitcoin mining stocks Marathon Digital Holdings Inc (MARA), Riot Platforms Inc (RIOT), and CleanSpark Inc (CLSK) are trading higher due to a surge in Bitcoin's price, which crossed $45,000. The rise is attributed to optimism about a potential spot Bitcoin ETF and expectations of Federal Reserve rate cuts in 2024. The SEC may soon decide on the ETF applications, with 14 asset managers seeking approval. As Bitcoin miners, MARA, RIOT, and CLSK are gaining investor attention with Bitcoin reaching its highest levels in nearly 21 months.

Portfolio Pulse from Adam Eckert

January 02, 2024 | 1:49 pm

NVDA

Nvidia's AI processors are expected to remain a significant growth driver for the PC and server markets in 2024, as indicated by sources from component and peripheral suppliers.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:48 pm

MU

SSNLF

Memory chip vendors, including Samsung Electronics and Micron Technology, are reportedly planning to increase DRAM prices by 15-20% in Q1 of 2024, as per sources from memory module houses.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:48 pm

NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:45 pm

TSLA

Tesla reported Q4 deliveries of 461,538 units for Model 3/Y and production of 476,777 units. Deliveries for other models stood at 22,969 units.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:44 pm

TSLA

Tesla Inc reported Q4 production of approximately 495,000 vehicles and deliveries of over 484,000 vehicles. For the full year of 2023, Tesla's vehicle deliveries grew by 38% year-over-year to 1.81 million, while production increased by 35% year-over-year to 1.85 million.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:43 pm

CLSK

LBPH

MARA

RIOT

VYGR

Longboard Pharmaceuticals (LBPH) reported positive topline data from its PACIFIC 1b/2a clinical trial of Bexicaserin, with a 53.3% median seizure reduction compared to 20.8% for the placebo group. Voyager Therapeutics (VYGR) announced a capsid license agreement and strategic collaboration with Novartis for gene therapy advancement. Crypto-related stocks like Marathon Digital Holdings (MARA), Riot Blockchain (RIOT), and CleanSpark (CLSK) saw an uptick as Bitcoin's value surpassed $45,000.

Portfolio Pulse from ryanfaloona@benzinga.com

January 02, 2024 | 1:42 pm